AKYA NASDAQ
Akoya Biosciences, Inc.
1W: +0.0%
1M: +4.9%
3M: +3.2%
1Y: -44.2%
3Y: -90.5%
$1.29
Last traded 2025-07-16 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships0
As Filer
counterparties named
5
As Counterparty
mentioned by others
2023-12-08
Earliest Filing
2025-07-08
Latest Filing
Mentioned As Counterparty
5 mentionsOther companies that named AKYA in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| QTRX Quanterix Corp | acquirer | Target company acquired by Quanterix Corporation in a merger transaction. | 2025-07-08 | View |
| QTRX Quanterix Corp | acquirer | Target company in the merger agreement with Quanterix Corporation. | 2025-04-29 | View |
| QTRX Quanterix Corp | acquirer | Target company in proposed merger with Quanterix; issuer of convertible notes in private placement. | 2025-04-04 | View |
| QTRX Quanterix Corp | acquirer | Target company in the merger agreement with Quanterix Corporation. | 2025-01-10 | View |
| ACRV Acrivon Therapeutics, Inc. | partner | Third Amendment to OncoSignature Diagnostic Agreement for ACR-368 companion diagnostic development | 2023-12-08 | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR